SCHEMBL6323264

SCHEMBL6323264

CCCCCc1ccc(S(=O)(=O)NC(C)CO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.53
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.49
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
SPHK1 Q9NYA1 3/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
AKT1 P31749 8/20 0.47
KDM4E B2RXH2 1/20 0.47
PDPK1 O15530 1/20 0.47
ABCB11 O95342 1/20 0.47
AKT2 P31751 1/20 0.47
GAB1 Q13480 1/20 0.47
AKT3 Q9Y243 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323269 1.00 CA2 (0.53) CA2LMNAHTTSMN1; SMN2NPSR1
SCHEMBL6329003 0.81 SMN1; SMN2 (0.51) CA2LMNAHTTSMN1; SMN2NPSR1
SCHEMBL6329000 0.81 SMN1; SMN2 (0.51) CA2LMNAHTTSMN1; SMN2NPSR1
SCHEMBL6323743 0.80 MMP13 (0.54) CA2LMNAHTTSMN1; SMN2CA12
SCHEMBL6323272 0.77 LMNA (0.58) CA2LMNAHTTSMN1; SMN2CA12
SCHEMBL4752500 0.77 CA2 (0.68) CA2SMN1; SMN2CA12CA9ALDH1A1
SCHEMBL16519485 0.77 CA2 (0.68) CA2SMN1; SMN2CA12CA9ALDH1A1
SCHEMBL26965400 0.77 CA2 (0.64) CA2LMNAHTTSMN1; SMN2CA12
SCHEMBL16519484 0.77 CA2 (0.68) CA2SMN1; SMN2CA12CA9ALDH1A1
SCHEMBL6324018 0.77 ADAMTS4 (0.53) CA2SMN1; SMN2NPSR1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA2 492/4885LMNA 2367/4885HTT 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.